DNA

Ginkgo Bioworks Holdings, Inc. [DNA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

DNA Stock Summary

Top 10 Correlated ETFs

DNA


Top 10 Correlated Stocks

DNA


In the News

02:59 26 Feb 2024 DNA

2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value

Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.

01:59 26 Feb 2024 DNA

7 Stocks Cathie Wood Is Still Loading Up On in Q1

You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.

01:25 26 Feb 2024 DNA

2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street

The average analyst following Ginkgo Bioworks thinks the stock can climb 140% from recent prices over the next 12 months or so. The consensus price target on Intellia Therapeutics suggests it can more than triple your money from recent prices.

12:01 26 Feb 2024 DNA

3 Healthcare Stocks at 52-Week Lows: Buy or Bye?

Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%.

11:55 26 Feb 2024 DNA

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought This Week

Cathie Wood bought shares of Meta Platforms, Recursion Pharmaceuticals, and Ginkgo Bioworks this week. Shares of Meta have more than tripled since bottoming out in late 2022.

09:35 26 Feb 2024 DNA

3 Pricey Stocks I'll Be Watching Like a Hawk in 2024

Eli Lilly's valuation is through the roof, but it's not just hot air. Ginkgo Bioworks could become a great long-term pickup.

06:00 26 Feb 2024 DNA

3 Cathie Wood Stocks to Start Off Your New Year Right

Cathie Wood has loaded up her portfolio with tomorrow's potential healthcare game changers. The superstar investor's commitment to innovation helped her flagship fund jump more than 60% last year.

08:10 26 Feb 2024 DNA

Could Ginkgo Bioworks Stock Help You Become a Millionaire?

Ginkgo Bioworks is a cell programming specialist that has partnered with many big companies. It is in a very early stage, but has a lot of promising opportunities in the long run.

11:30 26 Feb 2024 DNA

2 Cathie Wood Stocks That Might Be Smart Buys Right Now

Cathie Wood's focus on disruptive technologies could be a winning strategy over the long term. Ginkgo Bioworks and Recursion Pharmaceuticals are two of her more intriguing holdings in the biotech industry.

01:00 26 Feb 2024 DNA

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.

DNA Financial details

Company Rating
Neutral
Market Cap
2.8B
Income
-855.33M
Revenue
314.99M
Book val./share
0.64
Cash/share
0.54
Dividend
-
Dividend %
-
Employees
1.29K
Optionable
No
Shortable
Yes
Earnings
01 Mar 2024
P/E
-3.44
Forward P/E
-10.15
PEG
0.52
P/S
10.16
P/B
2.35
P/C
2.44
P/FCF
-7.89
Quick Ratio
6.6
Current Ratio
6.78
Debt / Equity
0.32
LT Debt / Equity
0.32
-
-
EPS (TTM)
-0.45
EPS next Y
-0.13
EPS next Q
1.58
EPS this Y
-7.41%
EPS next Y
-71.78%
EPS next 5Y
-71.78%
EPS last 5Y
-
Revenue last 5Y
37.19%
Revenue Q/Q
-31.2%
EPS Q/Q
78.57%
-
-
-
-
SMA20
14.63%
SMA50
5.22%
SMA100
-19.89%
Inst Own
58.56%
Inst Trans
0.94%
ROA
-42%
ROE
-56%
ROC
-0.5%
Gross Margin
75%
Oper. Margin
-292%
Profit Margin
-272%
Payout
-
Shs Outstand
2.12B
Shs Float
1.72B
-
-
-
-
Target Price
7.09
52W Range
1.12-2.545
52W High
-34%
52W Low
+32%
RSI
47.39
Rel Volume
0.44
Avg Volume
21.49M
Volume
9.52M
Perf Week
-2.22%
Perf Month
-6.38%
Perf Quarter
-43.59%
Perf Half Y
-26.26%
-
-
-
-
Beta
1.297
-
-
Volatility
0.09%, 0.1%
Prev Close
0%
Price
1.32
Change
-1.49%

DNA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2001-12-312019-12-312020-12-312021-12-31 2022-12-31
2K2.02K2.02K2.02K2.02K
Revenue per share
00.040.050.230.28
Net income per share
0-0.08-0.09-1.35-1.25
Operating cash flow per share
0-0.03-0.09-0.19-0.15
Free cash flow per share
0-0.05-0.13-0.23-0.18
Cash per share
000.261.140.78
Book value per share
000.311.111.03
Tangible book value per share
000.311.120.93
Share holders equity per share
000.311.111.03
Interest debt per share
000.010.020.26
Market cap
015.03B15.03B11.3B2.84B
Enterprise value
-902.54M014.67B9.77B1.96B
P/E ratio
0-125.39-118.6-6.15-1.35
Price to sales ratio
0277.37196.0536.015.94
POCF ratio
0-336.49-110.64-44.52-11.25
PFCF ratio
0-224.71-77.61-36.41-9.32
P/B Ratio
0032.577.511.63
PTB ratio
0032.577.511.63
EV to sales
-9.180191.3131.144.11
Enterprise value over EBITDA
4.110-136.4-5.21-0.9
EV to operating cash flow
6.190-107.97-38.51-7.79
EV to free cash flow
6.190-75.73-31.49-6.45
Earnings yield
0-0.01-0.01-0.16-0.74
Free cash flow yield
00-0.01-0.03-0.11
Debt to equity
0.2400.040.020.25
Debt to assets
0.1600.030.010.17
Net debt to EBITDA
4.1103.380.810.4
Current ratio
8.3805.8312.798.38
Interest coverage
0-29.57-57.45-770.53-20.84K
Income quality
0.070.371.070.140.12
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.790.540.52.752.99
Research and developement to revenue
1.021.782.083.662.2
Intangibles to total assets
0.0700.010.020.07
Capex to operating cash flow
00.50.430.220.21
Capex to revenue
0-0.41-0.75-0.18-0.11
Capex to depreciation
0-2.07-4.17-1.94-1.18
Stock based compensation to revenue
19.640.010.015.124.04
Graham number
000.775.85.4
ROIC
00-0.28-1.18-0.85
Return on tangible assets
00-0.19-0.91-0.89
Graham Net
000.130.850.34
Working capital
1.28B0353.32M1.59B1.28B
Tangible asset value
1.57B0464.9M1.52B1.57B
Net current asset value
647.04M0221.44M1.22B647.04M
Invested capital
0.2400.040.020.25
Average receivables
00087.04M116.18M
Average payables
00011.04M9.32M
Average inventory
0003.05M3.86M
Days sales outstanding
300.460115.1174.3463.01
Days payables outstanding
00324.8323.0518.68
Days of inventory on hand
0063.979.467.8
Receivables turnover
1.2103.172.095.79
Payables turnover
001.1215.8419.54
Inventory turnover
005.7138.5846.8
ROE
00-0.27-1.22-1.21
Capex per share
0-0.01-0.04-0.04-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.040.050.040.040.03
Net income per share
-0.41-0.09-0.11-0.09-0.16
Operating cash flow per share
-0.02-0.06-0.05-0.04-0.04
Free cash flow per share
-0.03-0.07-0.06-0.05-0.04
Cash per share
0.80.710.630.570.54
Book value per share
0.880.940.840.780.64
Tangible book value per share
0.840.840.750.690.56
Share holders equity per share
0.880.940.840.780.64
Interest debt per share
0.040.250.210.210.21
Market cap
5.09B3.13B2.55B3.6B3.53B
Enterprise value
3.85B2.26B1.74B2.9B2.89B
P/E ratio
-1.9-4.5-3.11-5.19-2.91
Price to sales ratio
76.6431.931.5644.6463.7
POCF ratio
-179.79-29.94-28.12-48.91-48.01
PFCF ratio
-121.81-24.05-23.15-41.3-45.31
P/B Ratio
3.551.811.582.392.82
PTB ratio
3.551.811.582.392.82
EV to sales
57.9223.0121.6236.0152.05
Enterprise value over EBITDA
-5.87-9.66-9.11-18.21-73.89
EV to operating cash flow
-135.88-21.6-19.26-39.46-39.23
EV to free cash flow
-92.06-17.35-15.86-33.32-37.02
Earnings yield
-0.13-0.06-0.08-0.05-0.09
Free cash flow yield
-0.01-0.04-0.04-0.02-0.02
Debt to equity
0.040.250.250.270.32
Debt to assets
0.030.170.170.180.2
Net debt to EBITDA
1.93.734.194.3616.53
Current ratio
11.718.386.927.496.78
Interest coverage
-390.1-17.9637.900
Income quality
0.040.60.440.420.24
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
6.551.241.381.271.48
Research and developement to revenue
3.911.842.021.792.83
Intangibles to total assets
0.040.070.070.070.08
Capex to operating cash flow
0.480.240.210.180.06
Capex to revenue
-0.2-0.26-0.24-0.17-0.08
Capex to depreciation
-1.42-1.62-1.03-0.74-0.21
Stock based compensation to revenue
8.481.10.90.760.95
Graham number
2.851.411.421.251.5
ROIC
-0.42-0.08-0.09-0.08-0.14
Return on tangible assets
-0.37-0.07-0.09-0.08-0.16
Graham Net
0.590.310.240.190.17
Working capital
1.34B1.28B1.14B1.06B973.38M
Tangible asset value
1.36B1.57B1.44B1.34B1.09B
Net current asset value
1.03B647.04M517.68M435.04M368.14M
Invested capital
0.040.250.250.270.32
Average receivables
145.32M99.11M83.65M76.88M66.03M
Average payables
15.39M10.89M16.01M17.6M12.19M
Average inventory
6.98M5.11M3.44M1.45M230.5K
Days sales outstanding
156.975.5194.6276.99102.52
Days payables outstanding
41.3331.1386.7767.79139.79
Days of inventory on hand
21.391310.091.940.91
Receivables turnover
0.571.190.951.170.88
Payables turnover
2.182.891.041.330.64
Inventory turnover
4.216.928.9246.2898.9
ROE
-0.47-0.1-0.13-0.12-0.24
Capex per share
-0.01-0.01-0.01-0.010

DNA Frequently Asked Questions

What is Ginkgo Bioworks Holdings, Inc. stock symbol ?

Ginkgo Bioworks Holdings, Inc. is a US stock , located in Boston of Ma and trading under the symbol DNA

Is Ginkgo Bioworks Holdings, Inc. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $7.09. The lowest prediction is $4.35 and the highest is $12

What is DNA stock prediction ?

What is Ginkgo Bioworks Holdings, Inc. stock quote today ?

Ginkgo Bioworks Holdings, Inc. stock price is $1.32 today.

Is Ginkgo Bioworks Holdings, Inc. stock public?

Yes, Ginkgo Bioworks Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap